|
Parameter
| |
Univariable analysis
|
Multivariable analysis
|
|---|
|
Hazard ratio
|
95% CI
|
p value
|
Hazard ratio
|
95% CI
|
p value
|
|---|
|
Intrinsic subtype
|
TNBC vs non-TNBC
|
1.053
|
0.281–3.344
|
0.933
|
0.632
|
0.137–2.710
|
0.535
|
|
Intrinsic subtype
|
HER2 vs non-HER2
|
2.060
|
0.543–13.41
|
0.314
|
1.721
|
0.353–12.53
|
0.517
|
|
Age at operation
|
≤56 vs >56
|
6.096
|
1.606–39.67
|
0.006
|
6.543
|
1.563–47.40
|
0.008
|
|
Tumor size (cm)
|
≤2 vs >2
|
3.234
|
0.445–40.56
|
0.049
|
2.811
|
0.874–46.08
|
0.062
|
|
Lymph node status
|
Negative vs Positive
|
4.493
|
0.873–82.10
|
0.077
|
7.035
|
1.195–137.4
|
0.028
|
|
Nuclear grade
|
1–2 vs 3
|
1.805
|
0.482–5.730
|
0.353
|
12.79
|
1.591–163.3
|
0.016
|
|
Ki67 (%)
|
≤14 vs >14
|
2.048
|
0.652–6.942
|
0.218
|
13.99
|
2.063–203.4
|
0.005
|
|
Pathological response
|
pCR vs non-pCR
|
2.075
|
0.619–9.357
|
0.248
|
1.561
|
0.301–10.34
|
0.609
|
|
plakoglobin
|
High vs Low
|
3.719
|
1.100–11.66
|
0.036
|
7.371
|
1.596–44.23
|
0.011
|
|
E-cadherin
|
Low vs High
|
2.223
|
0.709–7.517
|
0.169
|
5.003
|
0.966–35.14
|
0.055
|
-
HER2 human epidermal growth factor receptor 2; CI confidence interval; pCR pathological complete response; TNBC triple-negative breast cancer
